Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Aromatase Inhibitor Therapy
100%
Practical Guidance
100%
Women with Breast Cancer
75%
Fracture Risk
50%
Bone Loss
37%
T-score
37%
Fracture Risk Factors
37%
Zoledronic Acid
25%
Risk Factors
25%
Bone Mineral Density
25%
Postmenopausal Women
12%
Clinical Evidence
12%
Bisphosphonate Therapy
12%
Low Body Mass Index
12%
Randomized Clinical Trial
12%
Clinically Significant
12%
Clinical Practice Guidelines
12%
Treatment Recommendations
12%
Population-based
12%
Changes in Risk
12%
High-risk Women
12%
Evidence-based Medicine
12%
Current Treatment
12%
Meeting Abstracts
12%
Vitamin D Supplementation
12%
Pertinent Information
12%
Risk Status
12%
Prospective Clinical Trial
12%
Bisphosphonate Treatment
12%
Low BMI
12%
Associated Risk Factors
12%
Osteopenia
12%
Incremental Risk
12%
Fracture Rate
12%
Long Follow-up
12%
BMI Index
12%
Evidence-based Support
12%
Age-matched
12%
Medicine and Dentistry
Osteolysis
100%
Aromatase Inhibitor
100%
Breast Cancer
60%
Body Mass Index
30%
Zoledronic Acid
20%
Bone Density
20%
Bisphosphonate
20%
Clinical Trial
10%
Isotopes of Calcium
10%
Systematic Review
10%
Postmenopause
10%
Vitamin D
10%
Evidence-Based Medicine
10%
Randomized Clinical Trials
10%
Nursing and Health Professions
Aromatase Inhibitor
100%
Breast Cancer
60%
Bone Density
20%
Bisphosphonic Acid Derivative
20%
Zoledronic Acid
20%
Clinical Trial
20%
Practice Guideline
10%
Body Mass
10%
Vitamin D
10%
Systematic Review
10%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase Inhibitor
100%
Breast Cancer
60%
Zoledronic Acid
20%
Bisphosphonic Acid Derivative
20%
Clinical Trial
10%
Randomized Clinical Trial
10%
Vitamin D
10%